JNJ : Analysis & Opinions

  1. Hedge Funds Love These 3 Pharma Stocks

    April 14, 2014
    In 2012, the star performer among sectors was the financial sector. In 2013, it was consumer discretionary stocks. For 2 ...
  2. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  3. Bull of the Day: Quintiles (Q) - Bull of the Day

    March 5, 2014
    Bull of the Day: Quintiles (Q) - Bull of the Day
  4. How To Smooth-Out Your Ride In The Stock Market

    March 3, 2014
    Volatility is back. For investors, this nasty problem of gyrating markets can be a real hindrance to your portfolio’s total ...
  5. Earnings Front & Center - Ahead of Wall Street

    January 21, 2014
    The overall tone of the reports this morning is positive, though some guidance is a bit on the soft side.
  6. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  7. Bull of the Day: Pharmacyclics (PCYC) - Bull of the Day

    October 31, 2013
    Bull of the Day: Pharmacyclics (PCYC) - Bull of the Day
  8. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  9. 14 Companies That Have Raised Their Dividends For 50 Years Or ...

    September 10, 2013
    Imagine if you had bought these stocks 20 years ago.If you had, then right now you'd be earning dividend yields of... ...
  10. MedTech Industry Stock Update - Sept 2013 - Industry Outlook

    September 10, 2013
    MedTech Industry Stock Update - Sept 2013 - Industry Outlook
  11. The Street Has Caught Covidien

    August 1, 2013
    Covidien's quality isn't the issue, but Wall Street's love for it may be.
  12. After A Sharp Pullback, Is Allergan Pretty Enough?

    July 31, 2013
    Down on fears about generics and the pipeline, the Street may be underestimating Allergan
  13. Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook

    July 30, 2013
    Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook
  14. Roche Delivering Leverage, But Still Needs Diversification

    July 29, 2013
    If Roche can balance out its sales mix, the long-term value could be quite compelling at present prices.
  15. Celgene Only Getting Started, But The Street's Already Looking ...

    July 26, 2013
    Biotech valuations are into the nose-bleed zone, but Celgene continues to execute very well.
  16. Stryker Seems Back On Track

    July 19, 2013
    Stryker's revenue growth looks fine, but there are still pressures in the end markets.
  17. Intuitive Surgical Burning Up On Re-Entry

    July 19, 2013
    Intuitive Surgical has to reset expectations, and that's leading to a painful reassessment of the fair value.
  18. Where Do The Bears Go Next With St. Jude Medical?

    July 18, 2013
    St. Jude continues to defy bearish expectations of major share loss, but the shares aren't exactly cheap today.
  19. Positive Start to Q2 Earnings Season - Ahead of Wall Street

    July 16, 2013
    Though heavily Finance weighted at this stage, the early reports are
  20. Stock Market News for July 15, 2013 - Market News

    July 15, 2013
    Benchmarks posted marginal gains on Friday following better-than-expected results of few banking companies.
  21. Earnings Expectations for the Week of July 15

    July 14, 2013
    The earnings season ramps up this week, providing plenty of perspective on how the financial and technology sectors fared ...
  22. Q2 Earnings season get into high gear - Earnings Preview

    July 12, 2013
    Q2 Earnings season get into high gear - Earnings Preview
  23. Prestige Brands Gets Upgraded: Should You Be Buying?

    July 11, 2013
    At least two investment firms upgraded Prestige Brands' (NYSE:PBH) stock July 9 on news it had acquired a small Australian ...
  24. Hospira Touches 52-week High - Analyst Blog

    July 10, 2013
    Shares of Hospira soared to a 52-week high of $39.48 on Jul 9
  25. Intuitive Surgical's Miss Looks Systemic And Company-Specific

    July 9, 2013
    A surprising drop in U.S. system placements is going to put Intuitive Surgical in the penalty box.
  26. Bayer Announces Positive Phase I Data - Analyst Blog

    July 8, 2013
    Bayer announced positive results from a phase I study on PCCs.
  27. Profiting With Straddles This Earnings Season - Know Your Options

    July 2, 2013
    Profiting With Straddles This Earnings Season - Know Your Options
  28. Yet Another Setback for Bayer/JNJ's Xarelto - Analyst Blog

    July 2, 2013
    Bayer and Johnson & Johnson received a CRL from the FDA for Xarelto.
  29. Good News for Hospira, Shares up - Analyst Blog

    July 2, 2013
    The EMA's CHMP recommended the approval of Hospira's biosimilar version of Remicade.
  30. CHMP Positive on Dendreon's Provenge - Analyst Blog

    July 1, 2013
    The CHMP provided a positive opinion on Dendreon's marketing application for Provenge.
  31. Stock Market News for July 1, 2013 - Market News

    July 1, 2013
    Benchmarks ended a three day gaining streak on Friday as fears of the Federal Reserve scaling back the bond buying program ...
  32. Stock Market News for June 27, 2013 - Market News

    June 27, 2013
    Weaker-than-expected GDP numbers eased investor concerns that the Federal Reserve would decrease monetary stimulus in the ...
  33. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  34. Data from Bayer/JNJ's Xarelto Study - Analyst Blog

    June 25, 2013
    Bayer's announced that it will present data from a Xarelto clinical program.
  35. Rising 10-Year Yields Could Crush Popular Dividend ETFs

    June 21, 2013
    Seduced by backward-looking dividend increase streaks, investors have fallen in love with dividend ETFs such as the Vanguard ...
  36. Nektar's Pain Drug Impresses - Analyst Blog

    June 20, 2013
    Nektar announced encouraging top-line results from its HAL study on NKTR-181.
  37. Data on PCYC's ibrutinib - Analyst Blog

    June 20, 2013
    Pharmacyclics announced that data on ibrutinib was published in the NEJM.
  38. Priority Review for Gilead Drug - Analyst Blog

    June 10, 2013
    The NDA on Gilead's sofosbuvir will be reviewed on a priority basis by the FDA.
  39. Little Left To Dendreon But The Hope Trade

    May 10, 2013
    Dendreon looks increasingly irrelevant as the medical community moves on from Provenge.
  40. Recent Financials May Not Be Entirely Fair To Hologic

    May 8, 2013
    Macro pressures are outweighing solid internal progress at Hologic.
  41. In A Growth-Starved Sector, Becton Dickinson Rules

    May 3, 2013
    Becton Dickinson is a great business, but investors seem to be too willing to overpay for today's relatively stronger growth. ...
  42. It Gets A Little Harder From Here For Covidien

    April 29, 2013
    Expectations are the bigger issue for Covidien, as underlying growth is still pretty good on a relative basis.
  43. Is Controversy About Robot-Assisted Surgery Showing In Intuitive ...

    April 19, 2013
    Uncertainty about procedure growth may be opening a window in these often-expensive shares
  44. Broad Weakness Makes It Harder To Like St. Jude Today

    April 18, 2013
    Although I do believe the long-term expectations for St. Jude are increasingly beatable, this could be a frustrating stock ...
  45. Pharma Is Doing All The Pulling For Johnson & Johnson

    April 17, 2013
    Although JNJ reported decent earnings and has some major new drugs lined up - downside risk is definitely still present.
  46. 'Great Rotation': Fact or Fiction - Analyst Blog

    February 11, 2013
    Domestic stock funds garnered a whopping $21 billion in the initial four weeks of 2013, according to Lipper. This was the ...
  47. Pipeline Setback for Idenix - Analyst Blog

    February 7, 2013
    Idenix Pharmaceuticals, Inc. (IDIX) recently announced that the company has decided to discontinue its clinical development ...
  48. Elan Beats on Sales, Loses Tysabri - Analyst Blog

    February 7, 2013
    Elan Corporation (ELN) reported earnings of 15 cents per share for the fourth quarter of 2012 compared to the year-ago loss ...
  49. Bayer, J&J Collaborate with Portola - Analyst Blog

    February 6, 2013
    Bayer's (BAYRY) Healthcare unit and Johnson & Johnson's (JNJ) Janssen Pharmaceuticals recently collaborated with Portola ...
  50. LRY Unveils $55M Project - Analyst Blog

    February 5, 2013
    Yesterday, Liberty Property Trust (LRY) - a hybrid real estate investment trust (REIT) - unveiled its plan to construct an ...
  51. Stock Market News for January 30, 2013 - Market News

    January 30, 2013
    Better-than-expected quarterly results once again guided the S&P 500 and the Dow Jones into the green on Tuesday. Strong ...
  52. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  53. Stock Market News for January 23, 2013 - Market News

    January 23, 2013
    Better-than-expected earnings from major companies lifted benchmarks into positive territory on Tuesday ahead of earnings ...
  54. Stryker Follows Its Rivals With A Big Investment In China

    January 22, 2013
    Stryker's acquisition of Trauson is the right deal at the right time.
  55. Market Awaiting Big Tech Earnings - Analyst Blog

    January 22, 2013
    Stocks will likely take a breather today given the mixed earnings picture emerging from a busy reporting day. The market ...
  56. Ahead of Wall Street - January 22, 2013 - Ahead of Wall Street

    January 22, 2013
    Tuesday, January 22, 2013 Stocks will likely take a breather today given the mixed earnings picture emerging from a busy ...
  57. Pfizer's Quillivant Launched - Analyst Blog

    January 17, 2013
    Pfizer Inc. (PFE) recently announced that it has launched its attention deficit hyperactivity disorder (ADHD) treatment, ...
  58. Glaxo Seeks Albiglutide Approval - Analyst Blog

    January 15, 2013
    GlaxoSmithKline (GSK) recently announced the submission of a marketing application to the US Food and Drug Administration ...
  59. Digital Realty Expands in Australia - Analyst Blog

    January 10, 2013
    In order to expand its Australian footprints, Digital Realty Trust Inc. (DLR) recently acquired an established data center ...
  60. Alkermes Maintains Fiscal 2013 View - Analyst Blog

    January 9, 2013
    Alkermes plc (ALKS) recently reaffirmed its view for fiscal 2013 (ending March 31, 2013). The company continues to expect ...
  61. Cooper Downgraded to Neutral - Analyst Blog

    December 26, 2012
    We downgrade our recommendation on The Cooper Companies (COO) to Neutral following its fiscal fourth quarter (ended October ...
  62. Myriad Alleviates to Outperform - Analyst Blog

    December 21, 2012
    Following a strong first quarter result and an encouraging guidance, we upgrade our recommendation on Myriad Genetics (MYGN), ...
  63. Encouraging News for Shire - Analyst Blog

    December 21, 2012
    Shire plc (SHPG) recently received some encouraging news from Europe regarding its attention deficit/hyperactivity disorder ...
  64. NVO Progresses with Pipeline - Analyst Blog

    December 20, 2012
    Novo Nordisk (NVO) recently completed a phase IIIa study on IDegLira, which is a combination of Tresiba (insulin degludec) ...
  65. Positive Data on Actelion Candidate - Analyst Blog

    December 19, 2012
    Actelion (ALIOF) recently announced positive results from a phase II study on its S1P1 modulator, ponesimod. Actelion is ...
  66. Merck Ties Up with GE Healthcare - Analyst Blog

    December 19, 2012
    Merck (MRK) is collaborating with GE Healthcare for the use of an investigational positron emission tomography (PET) imaging ...
  67. Glaxo's Anthrax Drug Gets FDA Nod - Analyst Blog

    December 18, 2012
    GlaxoSmithKline (GSK) recently announced that its inhalational anthrax candidate, raxibacumab, has received US Food and Drug ...
  68. CHMP Negative on Isis' Kynamro - Analyst Blog

    December 17, 2012
    The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently did not recommend ...
  69. J&J Files NDA for Combo Diabetes Drug - Analyst Blog

    December 14, 2012
    Janssen Research & Development, LLC, a part of the Johnson & Johnson (JNJ) family of companies, recently announced the submission ...
  70. Label Expansion for JNJ's Zytiga - Analyst Blog

    December 12, 2012
    Johnson & Johnson's (JNJ) Janssen recently announced that the FDA has granted approval for the label expansion of the company's ...
  71. Gilead Plans to Split Stock 2-for-1 - Analyst Blog

    December 11, 2012
    Recently, the board of directors at Gilead Sciences Inc. (GILD) authorized a two-for-one stock split. The action, which will ...
  72. Myriad Teams Up with Sanofi - Analyst Blog

    December 11, 2012
    Myriad RBM, a wholly-owned subsidiary of molecular diagnostic company Myriad Genetics Inc. (MYGN), has recently collaborated ...
  73. Merck's Alzheimer's Drug Progresses - Analyst Blog

    December 10, 2012
    Merck (MRK) recently moved its Alzheimer's disease candidate, MK-8931, into a phase II/III study (EPOCH). The study will ...
  74. Pharma & Biotech Stock Outlook - Dec 2012 - Zacks Analyst Interviews

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  75. Smith & Nephew's Costly Deal

    November 29, 2012
    Smith & Nephew is having to pay a pretty hefty price for this growth injection and this just isn't a sustainable long-term ...
  76. Gilead Reports Positive HCV Data - Analyst Blog

    November 29, 2012
    Gilead Sciences (GILD) recently presented encouraging top-line data from a phase III study (Positron) which evaluated its ...
  77. Abbott's Humira's Label Expanded - Analyst Blog

    November 28, 2012
    Abbott Labs (ABT) recently received approval for yet another indication of Humira (adalimumab). The European Commission approved ...
  78. Dividend Stocks Lose Luster? - Analyst Blog

    November 26, 2012
    The average dividend yield on S&P 500 stocks has approximately halved to 2% over time. While significant inflows to these ...
  79. Medtronic's Growth Looks Good, But Can It Last?

    November 22, 2012
    Medtronic may not be a super grower anymore, but it's doing better than the Street seems to acknowledge
  80. Incyte Progresses on RA Candidate - Analyst Blog

    November 20, 2012
    Incyte Corporation (INCY) and Eli Lilly and Company (LLY) recently announced positive results from an ongoing 24-week phase ...
  81. Alkermes Reverts to Neutral - Analyst Blog

    November 16, 2012
    We are reverting to a Neutral recommendation on Alkermes plc (ALKS) from Outperform as we believe that the stock is fairly ...
  82. Still Neutral on DexCom - Analyst Blog

    November 15, 2012
    Following the third quarter earnings release, we are maintaining our long-term 'Neutral' recommendation on DexCom (DXCM), ...
  83. Cooper Launches New Closure System - Analyst Blog

    November 7, 2012
    CooperSurgical, a part of The Cooper Companies (COO), a company focused on contact lens and women's health, recently revealed ...
  84. Endo Health Solutions Needs Some Solutions Of Its Own

    November 7, 2012
    Can Endo reestablish itself as a quality healthcare name?
  85. Disappointing Quarter from Vertex - Analyst Blog

    November 5, 2012
    Vertex Pharmaceuticals Inc. (VRTX) posted break-even (including stock-based compensation expense) results in the third quarter ...
  86. Is “Less Bad” As Good As It Gets For Dendreon?

    November 5, 2012
    Dendreon has made progress with its expenses, but the sluggish revenue growth is still the major problem.
  87. DexCom Continues to Incur Loss - Analyst Blog

    November 5, 2012
    DexCom (DXCM), a player in the glucose monitoring market, reported third quarter 2012 loss per share of 25 cents, higher ...
  88. Merck Beats on EPS, Narrows View - Analyst Blog

    October 26, 2012
    Merck & Co. (MRK) reported third quarter 2012 earnings per share (excluding special items) of 95 cents, a couple of cents ...
  89. Loss at Elan Wider than Expected - Analyst Blog

    October 25, 2012
    Elan Corporation's (ELN) loss of 5 cents per share (excluding special items) for the second quarter of 2012 was wider than ...
  90. Beat and Raise Quarter for Amgen - Analyst Blog

    October 24, 2012
    Amgen (AMGN) continued its strong performance in 2012 with third quarter earnings coming in at $1.66 per share, 23 cents ...
  91. GE's Results Reflect An Industrial Slowdown, But Valuation Isn't ...

    October 23, 2012
    GE may have disappointed, but the company and its stock are both in good shape today.
  92. These Companies Have Raised Their Dividends for 50 Consecutive ...

    October 18, 2012
    Imagine if you had bought these stocks 20 years ago. If you had, then right now you'd be earning dividend yields of... 27%... ...
  93. Taking Stock of the Q3 Earnings season - Analyst Blog

    October 17, 2012
    Less than impressive earnings results from Intel (INTC), IBM (IBM), and CSX Corp. (CSX) after the close cap a busy earnings ...
  94. Abbott Reports Encouraging HCV Data - Analyst Blog

    October 16, 2012
    Abbott Laboratories (ABT) recently announced promising data from the phase IIb Aviator trial evaluating the combination of ...
  95. Merck's MK-3102 Encourages - Analyst Blog

    October 11, 2012
    Merck (MRK) recently presented encouraging phase IIb data on its type II diabetes candidate, MK-3102, at the annual meeting ...
  96. Encouraging Data on J&J Candidate - Analyst Blog

    October 10, 2012
    Janssen Research & Development, LLC, a part of the Johnson & Johnson (JNJ) family of companies, recently presented encouraging ...
  97. New Indication for Abbott's Humira - Analyst Blog

    October 4, 2012
    Abbott Labs (ABT) recently announced that it has received approval for an additional indication of Humira (adalimumab) from ...
  98. Novartis Progresses with AIN457 - Analyst Blog

    October 1, 2012
    Switzerland-based pharmaceutical company, Novartis AG (NVS) recently announced phase II data on its pipeline candidate, AIN457 ...
  99. 3 ETFs In Focus As Election Nears

    September 27, 2012
    ETFs have earned the respect of countless investors as viable financial instruments well suited as core building blocs for ...
  100. Glaxo Back on a Neutral Path - Analyst Blog

    September 25, 2012
    GlaxoSmithKline plc (GSK) performed disappointingly in the second quarter of 2012, missing the Zacks Consensus Estimate both ...
  101. Bayer Seeks European Approval - Analyst Blog

    September 21, 2012
    The HealthCare unit of Bayer (BAYRY) announced recently that it has filed an application seeking approval to market its low-dose ...
  102. Myriad Remains Neutral - Analyst Blog

    September 21, 2012
    We have reaffirmed our Neutral recommendation on Myriad Genetics (MYGN) with a target price of $29.00. The company reported ...
  103. FDA Panel to Review Celgene Drug - Analyst Blog

    September 20, 2012
    Celgene Corporation (CELG) recently announced that Oncologic Drugs Advisory Committee (ODAC) of the US Food and Drug Administration ...
  104. Impax in Settlement Agreement - Analyst Blog

    September 20, 2012
    Impax Laboratories, Inc. (IPXL) and Teva Pharmaceuticals USA, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries ...
  105. Bayer Upped to Outperform - Analyst Blog

    September 19, 2012
    Encouraged by strong second quarter 2012 results, an upbeat guidance and a series of positive subsequent developments, we ...
  106. Back to Neutral on Alkermes - Analyst Blog

    September 18, 2012
    We are moving back to a Neutral recommendation on Alkermes plc (ALKS) as we believe the stock is fairly valued at current ...
  107. Shire Aims to Expand Vyvanse Label - Analyst Blog

    September 17, 2012
    Shire plc (SHPG) recently announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental ...
  108. Cooper Companies: A Strong Buy - Analyst Blog

    September 12, 2012
    Rising earnings estimates on the back of strong third quarter fiscal 2012 results helped Cooper Companies (COO) achieve a ...
  109. Cooper Tops, Raises FY12 View - Analyst Blog

    September 7, 2012
    The Cooper Companies (COO), a company focused on contact lens and women's health, reported third-quarter fiscal 2012 (ended ...
  110. Elan Starts Phase II ELND005 Study - Analyst Blog

    September 6, 2012
    Elan Corporation (ELN) recently initiated a phase II placebo-controlled, safety and efficacy study with oral ELND005. ELND ...
  111. ScoliScore Could Be A Needle-Mover For TBIO - Analyst Blog

    August 29, 2012
    ScoliScore Could Be A Needle-Mover For TBIO ScoliScore Could Be A Needle-Mover For TBIO Yesterday (8/28/2012) Transgenomic ...
  112. coliScore Could Be A Needle-Mover For TBIO - Analyst Blog

    August 29, 2012
    coliScore Could Be A Needle-Mover For TBIO Brian Marckx, CFA Yesterday (8/28/2012) Transgenomic (TBIO) announced an ...
  113. DexCom Remains Neutral - Analyst Blog

    August 27, 2012
    We reiterate our Neutral recommendation on DexCom Inc. (DXCM). Its second-quarter 2012 loss per share of 21 cents exceeded ...
  114. Hansen Medical Boosts IP Portfolio - Analyst Blog

    August 24, 2012
    Hansen Medical (HNSN), a global developer and manufacturer of intravascular robotics, recently announced the expansion of ...
  115. FDA Extends PFE Drug Review Period - Analyst Blog

    August 22, 2012
    The US Food and Drug Administration (FDA) recently extended its review period for Pfizer's (PFE) rheumatoid arthritis (RA) ...
  116. Pfizer Looks To Spin Off Animal Health Unit

    August 15, 2012
    Pfizer has filed plans to sell up to 20% of its animal-health unit in the first half of 2013 to focus on human pharmaceuticals. ...
  117. Elan to Split into Two Companies - Analyst Blog

    August 14, 2012
    Elan Corporation (ELN) recently announced its decision to split into two separate publicly traded companies. The spin-off, ...
  118. The Week Ahead In Healthcare

    August 13, 2012
    The performance of healthcare stocks (as measured by ETFs) has begun to falter a bit, likely in part because Johnson & Johnson ...
  119. The Week Ahead In Healthcare

    August 8, 2012
    The week ahead for healthcare stocks.
  120. DexCom Misses on EPS, Losses Climb - Analyst Blog

    August 7, 2012
    DexCom (DXCM), a player in the glucose monitoring market, reported second-quarter 2012 loss per share of 21 cents, higher ...
  121. Solid Quarter at ALKS, View Backed - Analyst Blog

    July 31, 2012
    Alkermes plc (ALKS) reported earnings of 28 cents per share (including depreciation and stock-based compensation expenses) ...
  122. More Healthy Alternatives To Zimmer

    July 30, 2012
    Zimmer has turned to cost cutting to keep total profit growth moving positively forward, but doesn't appear to have any answers ...
  123. Amgen Beats, Raises Guidance - Analyst Blog

    July 27, 2012
    Amgen (AMGN) continued its strong performance in 2012 with second quarter earnings coming in at $1.82 per share, 31 cents ...
  124. Mixed 3Q for Covidien, Profit Drops - Analyst Blog

    July 26, 2012
    Covidien plc (COV), a large-cap medical technology company, reported its adjusted earnings per share (from continuing operations) ...
  125. Pfizer, J&J Drug Fails in 1st Study - Analyst Blog

    July 24, 2012
    Pfizer, Inc. (PFE) recently announced highly-awaited top-line results on Alzheimer's disease candidate, bapineuzumab. Pfizer ...
  126. 4 Dividend ETFs With Higher Yields Than LQD

    July 24, 2012
    Once upon a time, the conventional wisdom was that investors should hold stocks as a source of long-term capital appreciation ...
  127. Company News for July 18, 2012 - Corporate Summary

    July 18, 2012
    "    The Coca-Cola Company (NYSE:KO) reported second quarter earnings per share of $1.22, beating the Zacks Consensus Estimate ...
  128. How to Hear What Bernanke Is Saying - Analyst Blog

    July 17, 2012
    The QE question will again be on many investors' minds today as Ben Bernanke testifies before the Senate Banking committee. ...
  129. Ahead of Wall Street - July 17, 2012 - Ahead of Wall Street

    July 17, 2012
    Tuesday, July 17, 2012 The QE question will again be on many investors' minds today as Ben Bernanke testifies before ...
  130. The Week Ahead In Healthcare

    July 16, 2012
    Healthcare stocks continue to outperform this year. Here's what you can expect for the sector in the week ahead.
  131. What Patent Cliff? Pharma ETFs Continue to Surge - ETF News And ...

    July 10, 2012
    For at least the past few years, investors in the health care segment have been focused in on big pharma and the segment's ...
  132. Setback for Chelsea Therapeutics - Analyst Blog

    July 6, 2012
    Chelsea Therapeutics International, Ltd. (CHTP) recently suffered a setback when the US Food and Drug Administration (FDA), ...
  133. GolinHarris Acquires Virgo Health - Analyst Blog

    July 6, 2012
    GolinHarris, a division of Interpublic Group (IPG) intends to acquire Virgo Heath, an independent UK-based Healthcare Communications ...
  134. The Week Ahead In Healthcare

    July 6, 2012
    Early July offers another slow week in healthcare.
  135. Gilead Seeks FDA OK for Cobicistat - Analyst Blog

    July 2, 2012
    Recently, Gilead Sciences, Inc. (GILD) announced that it has filed a marketing application seeking approval for its HIV candidate, ...
  136. June's Best Dow Stocks

    June 30, 2012
    The Dow Jones Industrial Average closed June and the second quarter in stellar fashion with an astounding 278-point gain ...
  137. Gilead Seeks FDA Approval - Analyst Blog

    June 28, 2012
    Recently, Gilead Sciences, Inc. (GILD) announced that it has filed a marketing application seeking approval for its HIV candidate, ...
  138. Health Care ETFs in Focus on Obamacare Supreme Court Decision ...

    June 27, 2012
    In what looks to be the biggest Supreme Court decision since Bush v. Gore, the highest court in the land will give its opinion ...
  139. Bio-Reference Labs Taking Advantage Of Esoteric Opportunities

    June 22, 2012
    The decision of whether to buy Bio-Reference really comes down to an investor's confidence in the growth prospects for the ...
  140. EMA Validates Gilead's Drug - Analyst Blog

    June 20, 2012
    Recently, Gilead Sciences, Inc. (GILD) announced that its marketing application seeking approval for its HIV candidate elvitegravir ...
  141. Perrigo in Neutral Lane - Analyst Blog

    June 14, 2012
    We have maintained our Neutral rating on Perrigo Company (PRGO) with a target price of $112.00. Our long-term recommendation ...
  142. ETF Trading Report: Swiss, Health Care ETFs In Focus - ETF News ...

    June 13, 2012
    Stocks had trouble staying above water during Wednesday's session as Jamie Dimon's testimony and weak retail sales weighed ...
  143. Covidien Promotes Zogenix's Product - Analyst Blog

    June 8, 2012
    The pharmaceutical unit of Covidien plc (COV) and Zogenix Inc. (ZGNX) have recently agreed to co-endorse a prescription medicine ...
  144. Cooper Misses, Tweaks Guidance - Analyst Blog

    June 8, 2012
    The Cooper Companies (COO), a company focused on contact lens and women's health, reported second-quarter fiscal 2012 (ended ...
  145. Abbott Presents Data on Humira - Analyst Blog

    June 7, 2012
    Abbott Labs (ABT) recently presented phase III data on its blockbuster drug, Humira, from two studies. While ABILITY-2 is ...
  146. The Trend In Rising Cancer Incidences

    June 5, 2012
    As the world continues to modernize and grow, global cancer incidences are expected to increase exponentially and pharmaceutical ...
  147. Rockwood Has Its Risks, But Also Some Apparent Value

    May 31, 2012
    Rockwood has economic risks, but offers real growth opporunities in higher-value lithium and ceramics.
  148. Company News for April 20, 2011 - Corporate Summary

    May 9, 2012
    • Johnson & Johnson (NYSE:JNJ) reported Q1 EPS of $1.35, ex-items, ahead of the Zacks Consensus Estimate of $1.25 per share. ...
  149. Volcano Corp. Misses by a Penny - Analyst Blog

    May 3, 2012
    Volcano Corp. Misses by a Penny - Analyst Blog
  150. Don't Underestimate Dividends In A Recession

    April 30, 2012
    Today, businesses that provide the most basic human needs - food and medicine - are paying above-normal rates of return.
  151. 3 Undervalued Tech-Sector Gems

    April 27, 2012
    Following are a trio of stocks that have yet to claw their way back to their perches before the global economic maelstrom ...
  152. 5 Easy Ways to Cash In on US Dividends

    April 26, 2012
    If you’re outside the US looking in, there are important pros and cons to adding exchange traded funds from America ...
  153. The Perfect Rx for Your Portfolio

    April 4, 2012
    These three big drug stocks offer attractive yields and relative safety heading into the more challenging summer months, ...
  154. 7 Great Names for Dividend Yield

    March 30, 2012
    Large, dividend-paying equities are good portfolio additions in this low-interest-rate environment, says asset manager Chip ...
  155. Ruling Or Not, Healthcare Still Wins

    March 29, 2012
    The Affordable Care Act finally goes in front of the Supreme Court. However, the Justice’s ruling may not matter. Healthcare ...
  156. Dividends That Will Keep Growing

    March 26, 2012
    The value that these companies have created over the years is mainly due to the dividends they pay out to investors.
  157. 5 Reasons to Love Dividend Growth

    March 15, 2012
    What a smart strategy for DIY investors: It’s idiot and inflation proof, it’s money for nothing…and best ...
  158. Birth Control Subsidies Slashed: Will Big Pharma Take A Hit?

    March 6, 2012
    Several states have already slashed birth control subsidies. Learn how this will affect pharmaceutical stocks.
  159. Medtronic In Recovery Mode

    February 27, 2012
    Medtronic's valuation is very appealing given its leadership position in the medical device industry.
  160. The 10 Must-Know Market Forces for 2012

    February 14, 2012
    For the first time since 2007, investors have multiple ways to succeed this year. Understanding how the lingering effects ...
  161. Finding Quality and Yield

    February 9, 2012
    The dividend yield theory helps Kelley Wright of Investment Quality Trends find value in the market. Here, he explains ...
  162. Procter & Gamble Feels The Pinch

    January 31, 2012
    U.S sales growth combined with rising input costs helped put a lid on the company's quarter.
  163. Colgate-Palmolive Has Growth, But It'll Cost Ya

    January 30, 2012
    Colgate has great growth, but a valuation to match.
  164. Health Care's Highest Yields

    January 30, 2012
    Some of the biggest and highest-yielding drug stocks are declining near attractive buy levels, giving income-oriented investors ...
  165. Stryker Leaning Away From Knees

    January 26, 2012
    A fair amount of future growth is already baked into Stryker’s valuation.
  166. The Long-Term Play In Lab Work

    January 16, 2012
    As drugmakers beef up their pipelines in this world of rising costs, the contract research sector should profit.
  167. The Hot ETF for 2012

    January 11, 2012
    Here's a look at the method behind the picking my annual Hot Hand, so even if the pick misfires, at least you can buy into ...
  168. A Better ETF for Metals Investors

    January 11, 2012
    The most common silver and gold ETFs may present risks unknown to most investors, says asset manager and analyst Mo Dawoud. ...
  169. Bristol-Myers Pays Up To Patch A Gap

    January 9, 2012
    Bristol-Myers recently bought Inhibitex, a company leading the way in developing a treatment for Hepatitis C.
  170. Don't Count Out Healthcare Stocks

    January 6, 2012
    The healthcare sector remains bogged down in a mire of regulation and dwindling spending.
  171. Slow And Steady ETFs Outperforming

    January 3, 2012
    Low volatility ETFs lead the way in 2011.
  172. 2011's Biggest Mergers and Acquisitions

    December 30, 2011
    M&A activity rebounded in a big way in 2011. Here's a look back at the biggest mergers and acquisitions during the year.
  173. 2011 - Another Sick Year For Larger Med-Tech

    December 29, 2011
    Larger healthcare companies are still getting sickly returns in the market.
  174. How to Evaluate Global Dividend Stocks

    December 22, 2011
    Dividend yield is the most important factor to use when evaluating investment opportunities, says London-based portfolio ...
  175. Stryker Falling Back To Earth

    December 16, 2011
    Stryker Corp's stock offers the potential for above-average shareholder returns with modest downside risk.
  176. Synovis Has To Bow Out To Get Some Love

    December 15, 2011
    Synovis is undervalued no longer.
  177. Uncertainty Still Means Discount For WellPoint

    November 30, 2011
    Uncertainty still means discount for WellPoint.
  178. Medtronic May Be A Heavyweight, But It Can Still Hit Hard

    November 28, 2011
    Medtronic has gone from over-loved to under-loved, and value investors should take note.
  179. Medtronic Stable In A Challenging Market

    November 25, 2011
    Medtronic's stock is worth a close look.
  180. Canadians, Look Before You Leap South

    November 22, 2011
    Before painting their portfolios red, white, and blue, Canadian income investors need to understand the drawbacks of playing ...
  181. Is Third Time The Charm For Gilead?

    November 22, 2011
    Gilead is going all in on Hep C, as it acquires Pharmasset in a massive deal.
  182. Covidien Delivers Once Again

    November 21, 2011
    Covidien is overlooked and undervalued.
  183. Medicis May Not Stay Independent

    November 10, 2011
    Medicis is well-run, but arguably too risky to stay independent.
  184. If CareFusion Can Execute, This Is A Major Bargain

    November 9, 2011
    CareFusion has to make some improvements, but it could really reward investors.
  185. Dendreon's Chinese Water Torture

    November 3, 2011
    Dendreon's Provenge continues to shape up as a major disappointment.
  186. Merck's Penance Has Gone On Long Enough

    October 31, 2011
    Merck won't grow fast, but it's quality is undervalued. It's time for investors to reevaluate it.
  187. Zimmer Looking To Escape Its Value Trap

    October 31, 2011
    Zimmer continues to trade at a very reasonable forward P/E.
  188. Big Dividends, Small Risk

    October 31, 2011
    Businesses that payout nice dividends can offer reasonable substitutes for some investors.
  189. Boogeymen That Keep CEOs Awake At Night

    October 28, 2011
    Executives of these high-profile companies have no shortage of fears to keep them awake at night.
  190. Abbott Has Benefited From Its Diversification

    October 25, 2011
    Why is Abbott deciding to break apart?
  191. Abbott Labs Joins The Separation Movement

    October 24, 2011
    Abbott is joining the separation movement that is sweeping across corporate America. The company plans to break into a medical ...
  192. St. Jude Still A Patient Trade

    October 24, 2011
    St. Jude's growth is lacking, today. However, it could be a winner for the patient investor.
  193. Stryker Scraping By

    October 24, 2011
    Stryker's growth is modest, but the stock potential is surprising.
  194. High Yielding Equities

    October 21, 2011
    Despite the market volatility, there are still some stocks and ETFs that pay above-average dividend yields.
  195. 5 Must-Know Stocks For Tuesday

    October 17, 2011
    Here are four companies that will be releasing their earnings on October 18.
  196. Can AngioDynamics Get Hearts Racing?

    October 11, 2011
    With a new CEO, a strong balance sheet, and good technology, investors might want to check out AngioDynamics. The comopany ...
  197. Is Jabil Quietly Loading Both Barrels?

    September 30, 2011
    Jabil's revenue is holding up better than its customers.
  198. Berkshire Buys Shares And Controversy

    September 29, 2011
    Berkshire announced its intention to buy back shares, but what does that mean for investors?
  199. Attractive Dividend Stocks To Watch

    September 27, 2011
    Dividend yields, despite how insignificant they may seem, are a major component of equity returns as times goes on
  200. Medtronic's Healthy Growth Outlook

    August 29, 2011
    Medtronic's stock deserves a close look.
  201. AAA-Rated Stocks Lead S&P 500

    August 25, 2011
    These four blue chips are the only S&P 500 companies with AAA credit ratings, a distinction that shows superior financial ...
  202. FDA May Change Medical Device Rules

    August 19, 2011
    Changes to the approval process for some medical devices could have big implications for both big and small companies in ...
  203. 5 Market Centurions

    August 17, 2011
    Age doesn’t always equate with strength, but in the business world, companies that have survived more than a century ...
  204. Bonds That Look Better Than Treasuries

    August 14, 2011
    Instability in the political and economic spheres has meant a shift from Treasuries to corporate bonds in recent weeks, writes ...
  205. Dendreon's Bull Story In Intensive Care

    August 10, 2011
    Dendreon shocks bulls with a poor revenue ramp for Provenge.
  206. BD Healthy, But No Great Bargain

    August 9, 2011
    BD is not the cheapest health care name, but it comes with a lot of quality.
  207. Hologic Holding Its Place

    August 8, 2011
    Hologic's volume is not great today, but business should improve more than the market currently believes.
  208. The Perpetual Boston Scientific Turnaround Story

    August 4, 2011
    Another quarter brings another hope for better days at BSX.
  209. Covidien's Image Starting To Change

    August 3, 2011
    Find out why Covidien is much better than many investors assume.
  210. 4 Income Stocks Safer than Treasuries

    July 29, 2011
    With the wrangling in Washington sending more a signal of concern than comfort, the concept of safety is getting turned on ...
  211. Bard Not So Bulletproof

    July 29, 2011
    A high valuation magnifies a bump in Bard's growth.
  212. Don't Underestimate Dividends In A Recession

    July 29, 2011
    Today, businesses that provide the most basic human needs - food and medicine - are paying above-normal rates of return.
  213. 10 Drug Firms to Profit on Biosimilars

    July 28, 2011
    Over the next five years, the market for "biosimilars" is forecast to climb to $10 billion worldwide, as many brand-name ...
  214. Baxter Looking Pale In Comparison To Rivals

    July 26, 2011
    A handful of health care peers trade at more appealing earnings multiples than Baxter.
  215. St. Jude's Healthy Prognosis

    July 26, 2011
    St Jude continued to grow robustly during its second quarter.
  216. Stryker's Diversification Paying Off

    July 22, 2011
    Stryker keeps finding a way to pull growth out of the med-tech market.
  217. Kinetic's Roller Coaster Ride Comes To An End

    July 14, 2011
    Kinetic Concepts gets a fair deal for its volatile business.
  218. Better Budgets, Better Times For Robots

    July 12, 2011
    With healthier budgets at hospitals, robots are looking better and better.
  219. Immucor Passes Its Last Test

    July 5, 2011
    Immucor gets a fair price for its shareholders.
  220. Pleasure And Pain For Pfizer

    June 27, 2011
    Pfizer sees a new pain pill make it to market and another sent back to the drawing board.
  221. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  222. Attractive Dividend Stocks To Watch

    June 22, 2011
    Dividend yields, despite how insignificant they may seem, are a major component of equity returns as times goes on
  223. Will A Shake Up Cure AngioDynamics' Malaise?

    June 14, 2011
    AngioDynamics is shaking things up in the hopes of rekindling growth.
  224. Conglomerates With A Dividend Angle

    June 6, 2011
    Well-run conglomerates can be great additions to income-oriented portfolios.
  225. May's Dow 30 Winners and Losers

    June 1, 2011
    See the best and worst performing DJIA stocks from May 2011!
  226. Medtronic Still Muddling Through

    May 27, 2011
    Medtronic is going nowhere fast, but the quality hasn't left.
  227. Obagi's Pitfalls Provide Investment Opportunity

    May 24, 2011
    Obagi's stock dropped 24% after announcing a 13-cent loss in its first quarter. Find out why this presents an opportunity ...
  228. April's Dow 30 Winners and Losers

    May 2, 2011
    See the best and worst performing DJIA stocks from April 2011!
  229. What Becton Dickinson Lacks In Flash, It Makes Up For In Quality

    April 28, 2011
    Becton Dickinson is a great company with improving prospects that is ideal for long-term investors.
  230. 4 Stocks With A Better Debt Outlook Than The U.S.

    April 27, 2011
    One could argue that buying these businesses would be a safer bet than U.S. Treasuries if the shares were held over a period ...
  231. 6 Overbought Stocks To Watch

    April 25, 2011
    Let's take a look at a few stocks that have recently entered overbought territory because these could be candidates for a ...
  232. Stryker's In The Right Medical Space

    April 25, 2011
    Stryker is an appealing investment if growth levels return back to the double digits.
  233. Despite The Noise, Abbott Still A Value

    April 25, 2011
    Abbott has made some curious moves of late, but the value is still there.
  234. Intuitive And The High Price Of Scarcity

    April 21, 2011
    Intuitive needs more growth to maintain its valuation.
  235. Does Stryker Need Further Reconstruction?

    April 21, 2011
    Weakness in ortho is a concern, but Stryker looks attractively priced today.
  236. 4 Important Earnings Announcements For April 19

    April 18, 2011
    Earnings reports are significant events for every stock. Here are four earnings announcements for April 19.
  237. Endo Choosing The Less Traveled Path

    April 12, 2011
    Endo makes an unusual move to get into the device space.
  238. Staple Stocks Look Good In This Economy

    March 31, 2011
    These staples won't likely give you immediate returns - but during hard times, they can keep you from going under.
  239. Can Jabil Take The Next Step?

    March 24, 2011
    Jabil is showing some strong operating leverage today, but can the good times continue?
  240. Healthy Dividend-Growth Ideas In Healthcare

    March 16, 2011
    Healthcare is an increasingly worthwhile destination for dividend shoppers.
  241. DexCom Shows Diabetes Still A Growth Industry

    March 9, 2011
    DexCom shows that, although times are tough, people will still adopt better technology.
  242. Medicis - Generic Reprieve And Shareholder Relief

    March 2, 2011
    Medicis gets a big boost from patent settlements.
  243. Novavax Gets A Booster Shot From The Government

    March 1, 2011
    Novavax gets a sizable contract from the government that will largely fund its remaining clinical trials for flu vaccines.
  244. Multiple Value Creation Opportunities For Stryker

    February 2, 2011
    Stryker could end up being acquired by a larger rival, but company growth trends remain appealingly robust in their own right.
  245. Small Names With Big Dividends

    February 2, 2011
    Learn more about these small-cap companies that are providing tidy dividends to investors.
  246. 6 Important Earnings Announcements For January 25

    January 24, 2011
    Earnings reports are significant events for every stock. Here are 6 earnings announcement for January 25 that you should ...
  247. Large Cap Stocks For 2011 (WMT, PG, JNJ, CAT)

    January 7, 2011
    Many investment professionals are allocating assets to large cap quality names as they see the group as holding the most ...
  248. December's Best And Worst Performing Dow 30 Components

    January 3, 2011
    See the best and worst performing DJIA stocks of December 2010!
  249. Big Dividends In Large Caps

    December 17, 2010
    These five stocks pay good dividends and can help balance an otherwise unstable portfolio.
  250. Large Cap Bets For 2011

    December 9, 2010
    Many investment professionals are allocating assets to large cap quality names as they see the group as holding the most ...
  251. Procter Hardly A Gamble

    November 16, 2010
    While many are saying that now is an opportune time to take a closer look at ritzy retailer stocks, one shouldn't forget ...
  252. Expected Increase In Research And Development

    November 8, 2010
    Research & Development (R&D) is the key to success in the pharmaceutical industry, but just how much of an impact does it ...
  253. Kimberly-Clark On The Right Path

    November 4, 2010
    Consumer products companies have caught the attention of many investors and right now Kimberly-Clark.
  254. 5 Stocks That Are Haunting Investors

    October 27, 2010
    These stocks have given quite a scare to their investors, but the true horror lies in whether they can recover or not.
  255. The Best Health Care For Your Investment Dollar

    October 26, 2010
    The healthcare sector is looking like a strong area of the economy, and potentially a very lucrative investment.
  256. BIG Dividends, BIG Returns

    October 22, 2010
    High dividend paying stocks are present in many industries. But do you know how to analyze a balance sheet to ensure that ...
  257. Invest In The Lip Balm Portfolio

    October 5, 2010
    Themed portfolios can often exceed established ones in performance - and the lip balm portfolio is just one example.
  258. Stryker In Oversold Territory

    August 26, 2010
    A pessimistic stock market and weak Medtronic results have sent shares of Stryker back toward their lows over the last year.
  259. Boost Your Dividends With These Large Caps

    August 20, 2010
    These stocks will inject higher dividends into your portfolio.
  260. Cheap High-Yield Large Caps

    August 4, 2010
    Whether its foods, cigarettes, or Tylenol, today's large cap dividend plays offer a very compelling investment.
  261. AmerisourceBergen Continues to Impress

    July 28, 2010
    This drug distribution company is reaping the benefits of drug patent expiration and the government's new focus on healthcare.
  262. Investing In The Adspend Portfolio

    June 28, 2010
    Does advertising spending predict stock returns? Find out here.
  263. Value Picks From A Top Money Manager

    June 23, 2010
    Take a peek into the portfolios of a top performing, value-oriented money manager.
  264. Gilead's Uncertain Future

    April 26, 2010
    Despite a coming wave of patent expirations, Gilead's stock still deserves a further look.
  265. The Rest of the Story, After Earnings

    April 22, 2010
    The devil is in the details for some companies reporting earnings this week.
  266. 3 Not-So-Famous Stocks That Deserve The Spotlight

    March 22, 2010
    Popularity doesn't count in the stock market. We take a look at some lesser-known names investors should become acquainted ...
  267. Serious Dividend Yields For The Opportunistic Investor

    March 11, 2010
    Boring or not, dividends are valuable, especially when they are part a great business that has strong future earnings potential.
  268. Value-able Investing Lessons From Yacktman Funds

    March 10, 2010
    Yacktman's investing techniques can help individual investors outperform the market over the long haul.
  269. Asset OutFlows: A Contrarian Buy Signal

    March 2, 2010
    Money is fleeing the stock market once again. History says the time to buy is now.
  270. Liz Claiborne's Numbers Don't Add Up

    February 26, 2010
    Liz Claiborne CEO Bill McComb was a rising star in 2004. Five years later, he's struggling to turn around his iconic fashion ...
  271. 5 Stocks From The Davis Portfolio

    February 10, 2010
    The Davis New York Venture Fund's abnormal turnover rate makes it an intriguing fund to look at for long-term picks.
  272. Procter Hardly A Gamble

    January 25, 2010
    Basic necessities are a safe play no matter what the economic state.
  273. 5 Reasons Gold Is The Next Bubble To Burst

    January 22, 2010
    What goes up must come down.
  274. Dividend Yields You Won't Believe

    January 18, 2010
    When they can be obtained as part of an effort to buy quality companies on the cheap, dividends can create enormous value ...
  275. Alcoa Still Facing Tough Times

    January 15, 2010
    While the numbers certainly look to be heading in the right direction, they were not what analysts had expected.
  276. The Best Capital Allocator In Consumer Goods

    January 15, 2010
    These six stocks were chosen as favorites in the consumer goods field for 2010. Do they live up to the hype?
  277. Excellent Dividend Prospects In 2010

    January 7, 2010
    Today's best businesses are historically high dividend yields, and they shouldn't be ignored in 2010.
  278. Large Cap Bets For 2010

    January 6, 2010
    Many investment professionals are allocating assets to large cap quality names as they see the group as holding the most ...
  279. Smell Your Way To Profits

    November 24, 2009
    Matrixx Initiatives has taken it on the chin due to the product recall of its top-selling product.
  280. Four Stocks From The Heartland

    November 20, 2009
    If Bill Nasgovitz likes these stocks, you should too. This is the last of the Core Fore investing articles.
  281. No Surprises At Procter & Gamble

    November 2, 2009
    Overall, it's a big positive to have businesses as entrenched as P&G come out with a favorable outlook.
  282. McDonald's: Investors (And Employees) Are Lovin' It

    October 28, 2009
    McDonald's has one of the best 401(k) plans around. It's no wonder this stock is soaring.
  283. Kimberly-Clark Is Tough To Live Without

    October 20, 2009
    KMB sells things that few people will give up - no matter how bad the economic picture becomes - but that's not the only ...
  284. Long-Term Flu Plays

    October 2, 2009
    Flu vaccine shares still have long-term appeal.
  285. Funds With Low Fees And Commissions

    September 3, 2009
    Fees lead to diminishing returns, so it's best to invest in funds with little or no fees.
  286. Grandpa's Favorite Stocks

    August 20, 2009
    Luckily for investors, the stocks your grandpa loves have actually underperformed during this rally.
  287. Merck Unloved, But Not For Long

    July 23, 2009
    Merck's release was received without fanfare, but this solid company deserves another look.
  288. A Trio Of High Yielders With Strong Cash Positions

    July 21, 2009
    Here are some safe dividends with a 5% dividend or more, a rarity these days for stocks in the S&P 500.
  289. Three Stocks To Know For Next Week

    July 10, 2009
    Four big stocks to research before their earnings anouncements on Tuesday, July 14.
  290. A Rocky Week For Abbott Labs

    July 3, 2009
    This healthcare company has seen better weeks, but it's still too early to tell if recent bad news will pummel the stock.
  291. The Case For Clorox

    June 17, 2009
    Clorox just announced a raised dividend, but it's not the only promising play in the consumer goods sector.
  292. Don't Underestimate Dividends In A Recession

    May 15, 2009
    Today, businesses that provide the most basic human needs - food and medicine - are paying above-normal rates of return.
  293. Convertible Securities In Today's Market

    April 30, 2009
    John Calamos, the father of convertible investing, moderated a panel on convertible bonds at the Milken Global Conference ...
  294. Avoid Unions At All Costs

    April 24, 2009
    Misinformation thrown about in the auto bailout is a clear sign for investors to avoid companies with significantly unionized ...
  295. Baxter A Healthy Healthcare Holding

    April 22, 2009
    Baxter's recent results demonstrate why it continues as a leader in its industry and should be considered a core healthcare ...
  296. Economy's Down, But Some Dividends Are Up

    March 31, 2009
    Even in this trying economic climate, some companies are increasing their dividends. But, does this make them worthy of investment?
  297. Why A Merck/Schering Combo Makes Sense

    March 12, 2009
    The Merck/Schering marriage might be a winning combination for both the companies and investors.
  298. Healthcare Sensitivity According To The Dow

    February 25, 2009
    Beta is a good measure for investors to use, but it is not a guarantee.
  299. Investing In State Farm's Starting Five

    February 23, 2009
    Creativity is the key to developing investment ideas.
  300. An Even Rarer Stryker Buying Opportunity

    February 23, 2009
    Four months ago there was a buying opportunity for Stryker but is the opportunity better or worse now?
  301. Bristol-Myers To IPO Baby Formula Biz

    February 16, 2009
    This company's IPO of its Mead Johnson unit will serve as a litmus test for the health of the 2009 equities market.
  302. Medical Equipment Outlook The New Year

    December 30, 2008
    Could this medical device provider support your portfolio?
  303. Vertex Needs A Relaxation Shot

    December 19, 2008
    Vertex has seen some great volatility this year. Will the volatility continue?
  304. Making Your Investments Pay: Equity Income ETFs

    December 4, 2008
    The flight to extreme quality has reduced treasury yields to non-inflation beating instruments. Income ETFs are now ripe ...
  305. Five Insider Stocks For December 3

    December 3, 2008
    Best Buy has seen a flurry of insider buying in the last six months. Could the top brass be on to something?
  306. Wyeth's Day In Court

    November 6, 2008
    Wythe and other drug companies are anxiously awaiting the outcome a product labeling liability case before the U.S. Supreme ...
  307. A Matrixx For Killing The Common Cold

    November 3, 2008
    Matrixx Initiatives works to build a name for itself in the competitive over-the-counter cold medicine market.
  308. Aging Population Feeds Global Healthcare Demand

    October 30, 2008
    Investing in foreign-based healthcare providers is as important as investing in healthcare providers with a global reach.
  309. Abbott Labs A Salve For The Wounded Portfolio

    October 16, 2008
    Abbott Labs announced a new buyback program and development of a revolutionary heart stent. Long-term investors should take ...
  310. Pfizer Drug Development Ahead Of Schedule

    October 6, 2008
    Pfizer's late-stage drug pipeline has gone from 16 to 25 drugs in six months, and a high dividend cushions returns while ...
  311. Sleep Easy With Abbott Labs

    October 3, 2008
    Security and stability reign at Abbott Labs. The drug maker has avoided major recalls and has rock solid patent protection.
  312. Back To The Basics: Safety And Diversification

    September 19, 2008
    With investors freaking out, it is time to examine a small portfolio of stocks to gain diversification and safety.
  313. Investing In The Beijing Olympics

    August 20, 2008
    The Beijing Games have been in the media spotlight for months. Learn which sponsors, partners and suppliers are cashing in.
  314. Is Jarden's Basket Of Brands A Value Trap?

    August 4, 2008
    This brand manager owns many No.1 names, but it will have to perform flawlessly for several years to pay down its debt.
  315. Stocks That Love To Surprise Us For July 16

    July 16, 2008
    Companies that string together many quarters of positive earnings surprises are usually rewarded. This week the focus is ...
  316. Emulate Buffett For Fun And Profit - Mostly Profit

    June 23, 2008
    We take a peek at some of Berkshire Hathaway's top holdings to see what Warren Buffett sees.
  317. CVS Posts Record Profits

    May 5, 2008
    Despite the slowing U.S economy, CVS is still going strong.
  318. How To Play On Falling Consumer Confidence (PG, JNJ)

    September 5, 2007
    Consumer confidence is down, along with slumping retail and a housing slowdown. We examine safe picks for a cool market.
  319. Berkshire's Q2 Portfolio Shuffle Explained (BRK.A)

    August 17, 2007
    Glenn Curtis gives his take on the recent changes within Berkshire's portfolio.
  320. Take A Flier On Regional Air

    August 16, 2007
    There's plenty of risk (and perhaps some reward) in these small-cap airlines who feed the major hubs.
  321. Leap Of Faith Healing (MEDX, PDLI, AMLN)

    August 8, 2007
    Make the leap with three pharmaceutical companies who require investor courage but could provide a healthy return.
  322. Small Caps For Big Cures (VRTX, VRX, MLNM)

    July 27, 2007
    These three companies are on the cutting edge, but can they carve out big returns for investors?
  323. Ultimate Headache Relief (BAY)

    May 17, 2007
    Investors seeking big pharma exposure often confine themselves to the United States, but the best drug company just might ...
  324. As Good As New (BDX, BSX, ZMH)

    May 11, 2007
    A look at several companies poised to meet the healthcare needs of the aging baby-boomer generation
  325. Stick'em Up (JNJ, MMM, ICI)

    March 29, 2007
    Perhaps one of these three adhesive manufactures will help hold your portfolio together.
  326. P/E Ratios Still Matter

    February 1, 2007
    High P/E stocks are almost always more glamorous than their low P/E counterparts, but are they more profitable?
  327. Bristol-Myers Hurt By Plavix, Saved By Demographics (BMY)

    November 16, 2006
    Despite BMY's recent struggles with its Plavix sales, favorable demographics make the stock a good investment to consider.
  328. Boston Scientific Shaken, But Not Stirred (BSX)

    November 8, 2006
    Boston Scientific looks poised for higher per share valuations in the future.
  329. A Value Stock In A Growth Industry (BVF)

    September 20, 2006
    Uncertainty surrounding patent protection of antidepressant Wellbrutin makes Biovail a compelling investment.
  330. Weakness At Target A Reason For Concern (TGT)

    July 18, 2006
    With an economic slowdown in the mix, Target may feel the pinch more than investors expect.
  331. Pfizer, Pass the Rolaids

    June 12, 2006
    $15 billion for its consumer products unit won’t cure Pfizer’s ailing stock.
  332. Boston Scientific's Billion Dollar Response

    January 18, 2006
    The bidding war for Guidant Corporation continues to heat up.
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center